BRPI0508425A - análogos de fosfolipìdeo como agentes diapêuticas e seus métodos - Google Patents

análogos de fosfolipìdeo como agentes diapêuticas e seus métodos

Info

Publication number
BRPI0508425A
BRPI0508425A BRPI0508425-3A BRPI0508425A BRPI0508425A BR PI0508425 A BRPI0508425 A BR PI0508425A BR PI0508425 A BRPI0508425 A BR PI0508425A BR PI0508425 A BRPI0508425 A BR PI0508425A
Authority
BR
Brazil
Prior art keywords
agents
diaperutic
methods
phospholipid analogues
phospholipid
Prior art date
Application number
BRPI0508425-3A
Other languages
English (en)
Inventor
Jamey Weichert
Marc Longino
Anatoly Pinchuk
Original Assignee
Cellectar Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellectar Llc filed Critical Cellectar Llc
Publication of BRPI0508425A publication Critical patent/BRPI0508425A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0408—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

ANáLOGOS DE FOSFOLIPìDEO COMO AGENTES DIAPêUTICAS E SEUS MéTODOS. A presente invenção refere-se a métodos e usos de análogos de éter de fosfolipídeo como agentes de diagnóstico e terapêuticos para vários cânceres.
BRPI0508425-3A 2004-03-02 2005-03-02 análogos de fosfolipìdeo como agentes diapêuticas e seus métodos BRPI0508425A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52116604P 2004-03-02 2004-03-02
PCT/US2005/006681 WO2005084716A2 (en) 2004-03-02 2005-03-02 Phospholipid analogs for diagnosis and treatment of cancer

Publications (1)

Publication Number Publication Date
BRPI0508425A true BRPI0508425A (pt) 2007-07-24

Family

ID=34919310

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508425-3A BRPI0508425A (pt) 2004-03-02 2005-03-02 análogos de fosfolipìdeo como agentes diapêuticas e seus métodos

Country Status (17)

Country Link
US (3) US8535641B2 (pt)
EP (3) EP2044961B1 (pt)
JP (7) JP2007528374A (pt)
KR (1) KR20070015518A (pt)
CN (1) CN1929869B (pt)
AT (1) ATE437657T1 (pt)
AU (1) AU2005219412A1 (pt)
BR (1) BRPI0508425A (pt)
CA (1) CA2557698A1 (pt)
DE (1) DE602005015687D1 (pt)
DK (1) DK1729824T3 (pt)
ES (3) ES2330951T3 (pt)
HK (1) HK1130186A1 (pt)
IL (1) IL177645A0 (pt)
MX (1) MXPA06009681A (pt)
WO (1) WO2005084716A2 (pt)
ZA (1) ZA200607042B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006014589A2 (en) * 2004-07-08 2006-02-09 Cellectar, Llc Virtual colonoscopy with radiolabeled phospholipid ether analogs
KR20070015518A (ko) * 2004-03-02 2007-02-05 셀렉타, 엘엘씨 암의 진단 및 치료를 위한 포스포리피드 유사체
US8540968B2 (en) 2004-03-02 2013-09-24 Cellectar, Inc. Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
CA2591907A1 (en) * 2004-12-20 2007-02-01 Cellectar, Llc Phospholipid ether analogs for detecting and treating cancer
WO2009005509A1 (en) * 2006-08-15 2009-01-08 Cellectar, Inc. Near infrared-fluorescence using phospholipid ether analog dyes in endoscopic applications
US7893286B2 (en) 2007-06-01 2011-02-22 Cellectar, Inc. Method for the synthesis of phospholipid ethers
WO2008150439A1 (en) 2007-06-01 2008-12-11 Cellectar, Inc. Compositions of phospholipid ether boronic acids and esters and methods for their synthesis and use
WO2010011844A1 (en) * 2008-07-25 2010-01-28 Tufts Medical Center A system and method of clinical treatment planning of complex, monte carlo-based brachytherapy dose distributions
ES2549459T3 (es) 2009-05-11 2015-10-28 Cellectar, Inc. Compuestos de éter de fosfolípido fluorescentes, composiciones y procedimientos de uso
US7811548B1 (en) 2009-05-11 2010-10-12 Cellectar, Inc. Fluorescent phospholipid ether compounds and compositions
US8871181B2 (en) 2009-05-11 2014-10-28 Cellectar, Inc. Fluorescent phospholipid ether compounds, compositions, and methods of use
DK2440253T3 (da) * 2009-06-12 2020-07-20 Cellectar Inc Alkylphospholipidforbindelser til behandling af cancer og billeddannelse og detektering af cancerstamceller
US10007961B2 (en) * 2009-09-09 2018-06-26 Wisconsin Alumni Research Foundation Treatment planning system for radiopharmaceuticals
JP2013504590A (ja) * 2009-09-11 2013-02-07 セレクター，インコーポレイティド 非放射性リン脂質化合物、組成物、及び使用方法
WO2016081203A2 (en) 2014-11-17 2016-05-26 Cellectar Biosciences, Inc. Phospholipid ether analogs as cancer-targeting drug vehicles
US10265398B2 (en) 2015-11-06 2019-04-23 Wisconsin Alumni Research Foundation Long-lived gadolinium based tumor targeted imaging and therapy agents
US11467159B2 (en) * 2016-06-14 2022-10-11 Cellectar Biosciences, Inc. Luminescent phospholipid analogs for the identification and isolation of circulating tumor cells
US11147823B2 (en) * 2016-07-13 2021-10-19 Wisconsin Alumni Research Foundation Phospholipid ether analogs for imaging and targeted treatment of pediatric solid tumors
AU2017300361B2 (en) 2016-07-18 2024-08-01 Wisconsin Alumni Research Foundation Radiohalogenated agents for In Situ Immune Modulated Cancer Vaccination
US11633506B2 (en) * 2016-07-18 2023-04-25 Wisconsin Alumni Research Foundation Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
CA3031776C (en) * 2016-07-25 2024-02-20 Wisconsin Alumni Research Foundation Targeted radiotherapy chelates for in situ immune modulated cancer vaccination
WO2018022125A1 (en) * 2016-07-25 2018-02-01 Wisconsin Alumni Research Foundation Radioactive phospholipid metal chelates for cancer imaging and therapy
WO2018148224A1 (en) 2017-02-07 2018-08-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
JP7178355B2 (ja) 2017-02-28 2022-11-25 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための組成物および方法
EP3706808A1 (en) * 2017-11-10 2020-09-16 Wisconsin Alumni Research Foundation Using targeted radiotherapy (trt) to drive anti-tumor immune response to immunotherapies
US20190184040A1 (en) * 2017-12-15 2019-06-20 Wisconsin Alumni Research Foundation Targeted Macrocyclic Agents for Dual Modality PET and MRI Imaging of Cancer
CN112055595A (zh) 2018-01-22 2020-12-08 恩多塞特公司 Car t细胞的使用方法
WO2019156795A1 (en) * 2018-02-06 2019-08-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
KR20220080139A (ko) * 2019-10-10 2022-06-14 셀렉타 바이오사이언시스, 인코퍼레이티드 인지질-플라바글린 접합체 및 표적화된 암 치료를 위해 이를 사용하는 방법

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851526A (en) * 1985-04-19 1998-12-22 Ludwig Institute For Cancer Research Methods of treating colon cancer utilizing tumor-specific antibodies
US4873075A (en) * 1985-09-10 1989-10-10 The University Of Michigan Polyiodinated triglyceride analogs as radiologic agents
US5093042A (en) * 1985-09-10 1992-03-03 The University Of Michigan Polyiodinated triglyceride analogs as radiologic agents
US4957729A (en) * 1985-09-10 1990-09-18 The University Of Michigan Polyiodinated triglyceride analogs as radiologic agents
US4925649A (en) 1987-06-12 1990-05-15 The University Of Michigan Radioiodinated diacylglycerol analogues and methods of use
US5087721A (en) * 1987-10-23 1992-02-11 The University Of Michigan Radioiodinated phosphate esters
US4965391A (en) 1987-10-23 1990-10-23 The University Of Michigan Radioiodinated phospholipid ether analogues
US5347030A (en) * 1987-10-23 1994-09-13 The Board Of Regents Of The University Of Michigan Radioiodinated phospholipid ether analogues and methods of using same
US5041859A (en) * 1988-10-04 1991-08-20 Nikon Corporation Automatic focusing detection device for cameras
US5274113A (en) 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5369097A (en) 1991-04-25 1994-11-29 The University Of British Columbia Phosphonates as anti-cancer agents
US5783170A (en) * 1991-11-27 1998-07-21 Diatide, Inc. Peptide-metal chelate conjugates
US5626654A (en) 1995-12-05 1997-05-06 Xerox Corporation Ink compositions containing liposomes
US6255519B1 (en) 1996-12-04 2001-07-03 Regents Of The University Of Michigan Radioiodinated phospholipid ether analogs and methods of using the same
CA2276284C (en) 1996-12-04 2006-10-10 The Regents Of The University Of Michigan Radioiodinated phospholipid ether analogs and methods of using the same
US6503478B2 (en) 1999-01-13 2003-01-07 Lightouch Medical, Inc. Chemically specific imaging of tissue
ATE404217T1 (de) * 1999-06-24 2008-08-15 Univ British Columbia Therapie mit lipoproteinlipase (lpl) variant
EP1346041B1 (en) * 2000-11-27 2007-02-28 Praecis Pharmaceuticals Incorporated Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
JP4247110B2 (ja) * 2001-06-06 2009-04-02 ブルックヘブン サイエンス アソシエーツ 新規メタロポルフィリン及び放射線治療用放射線増感剤としてのそれらの使用
US7220539B1 (en) 2002-06-12 2007-05-22 The Salk Institute For Biological Studies Protein kinase B/Akt modulators and methods for the use thereof
CA2489469C (en) * 2002-06-14 2016-03-22 Immunomedics, Inc. Monoclonal antibody pam4 and its use for diagnosis and therapy of pancreatic cancer
CA2492878A1 (en) * 2002-07-19 2004-01-29 Ludwig Institute For Cancer Research Enhancing the effect of radioimmunotherapy in the treatment of tumors
WO2005028681A1 (en) 2003-09-19 2005-03-31 Arcturus Bioscience, Inc. Predicting breast cancer treatment outcome
WO2005063774A1 (en) 2003-12-22 2005-07-14 Johns Hopkins University Boronic acid aryl analogs
US7632644B2 (en) 2004-03-02 2009-12-15 Cellectar, Inc. Imaging and selective retention of phospholipid ether analogs
KR20070015518A (ko) 2004-03-02 2007-02-05 셀렉타, 엘엘씨 암의 진단 및 치료를 위한 포스포리피드 유사체
US8540968B2 (en) 2004-03-02 2013-09-24 Cellectar, Inc. Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
WO2006014589A2 (en) * 2004-07-08 2006-02-09 Cellectar, Llc Virtual colonoscopy with radiolabeled phospholipid ether analogs
EP1729790A4 (en) 2004-03-29 2009-09-30 Robin Polt AMPHIPATHIC GLYCOPEPTIDES
US20060115426A1 (en) 2004-08-11 2006-06-01 Weichert Jamey P Methods of detecting breast cancer, brain cancer, and pancreatic cancer
US7041859B1 (en) 2004-09-09 2006-05-09 University Of Tennessee Research Foundation Method for halogenating or radiohalogenating a chemical compound
CA2591907A1 (en) * 2004-12-20 2007-02-01 Cellectar, Llc Phospholipid ether analogs for detecting and treating cancer
WO2009005509A1 (en) 2006-08-15 2009-01-08 Cellectar, Inc. Near infrared-fluorescence using phospholipid ether analog dyes in endoscopic applications
WO2008150439A1 (en) * 2007-06-01 2008-12-11 Cellectar, Inc. Compositions of phospholipid ether boronic acids and esters and methods for their synthesis and use
US7893286B2 (en) 2007-06-01 2011-02-22 Cellectar, Inc. Method for the synthesis of phospholipid ethers
GB0819280D0 (en) 2008-10-21 2008-11-26 Gen Electric Imgaing and radiotherapy methods
DK2440253T3 (da) 2009-06-12 2020-07-20 Cellectar Inc Alkylphospholipidforbindelser til behandling af cancer og billeddannelse og detektering af cancerstamceller
WO2011031911A1 (en) 2009-09-11 2011-03-17 Cellectar, Inc. Deuterated alkyl phospholipid compounds, compositions, and methods of use
JP2013504590A (ja) 2009-09-11 2013-02-07 セレクター，インコーポレイティド 非放射性リン脂質化合物、組成物、及び使用方法

Also Published As

Publication number Publication date
US20050196339A1 (en) 2005-09-08
EP2044961B1 (en) 2013-07-17
JP6342818B2 (ja) 2018-06-13
EP2044960A2 (en) 2009-04-08
HK1130186A1 (en) 2009-12-24
EP2044961A3 (en) 2009-08-12
IL177645A0 (en) 2006-12-31
EP2044961A2 (en) 2009-04-08
EP1729824A2 (en) 2006-12-13
ES2430065T3 (es) 2013-11-18
ES2330951T3 (es) 2009-12-17
JP6228080B2 (ja) 2017-11-08
ZA200607042B (en) 2007-12-27
JP2007528374A (ja) 2007-10-11
EP1729824B1 (en) 2009-07-29
ES2440257T3 (es) 2014-01-28
DK1729824T3 (da) 2009-11-02
EP2044960A3 (en) 2009-11-04
JP6453818B2 (ja) 2019-01-16
CN1929869B (zh) 2010-11-24
MXPA06009681A (es) 2007-03-15
US9550002B2 (en) 2017-01-24
DE602005015687D1 (de) 2009-09-10
WO2005084716A2 (en) 2005-09-15
US8877159B2 (en) 2014-11-04
JP2017002060A (ja) 2017-01-05
JP2013040201A (ja) 2013-02-28
CN1929869A (zh) 2007-03-14
AU2005219412A1 (en) 2005-09-15
JP2017173339A (ja) 2017-09-28
WO2005084716A3 (en) 2006-06-01
EP2044960B1 (en) 2013-11-20
CA2557698A1 (en) 2005-09-15
JP2015071642A (ja) 2015-04-16
US20150093330A1 (en) 2015-04-02
US20140023587A1 (en) 2014-01-23
KR20070015518A (ko) 2007-02-05
ATE437657T1 (de) 2009-08-15
US8535641B2 (en) 2013-09-17
JP2012097113A (ja) 2012-05-24
JP2014210803A (ja) 2014-11-13

Similar Documents

Publication Publication Date Title
BRPI0508425A (pt) análogos de fosfolipìdeo como agentes diapêuticas e seus métodos
CR8919A (es) Analogos de tetrapeptidos
CL2011003346A1 (es) Compuestos derivados de 2,3-dihidro-5h-[1,3]tiazolo[3,2-a]pirimidin-5-ona, moduladores de pi3k; composicion farmaceutica; y uso para tratar una enfermedad de base inmunologica, cancer o enfermedad pulmonar en un paciente.
BRPI0607728A2 (pt) complexo de lipoproteìna carregado reconstituìdo, composição farmacêutica, e, uso de um complexo de lipoproteìna carregado
CR11017A (es) Anticuerpos anti-robo4 y sus usos
ITMI20052171A1 (it) Composti e-amminocarbonil bicicloepten pirimidindiamminici stereoisomericamente arricchiti e loro uso
BR112013003248A2 (pt) "macrociclo peptidomimético e seus usos"
CR9223A (es) 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas,asi como preparaciones farmaceuticas que las contienen
ATE507878T1 (de) Gerät für intensitätsmodulierte kleinraumbestrahlungstherapie
ME01532B (me) Jedinjenja
ATE451892T1 (de) Gerät zur remodellierung von weichem körpergewebe
GT200600092A (es) Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer
DE60239931D1 (de) Kombinationstherapie
IL187343A0 (en) Compositions and methods for the diagnosis and treatment of tumor
DK1628685T3 (da) Antivirale phosphonatanaloge
PA8667201A1 (es) Nuevos compuestos farmaceuticos
GT200600430A (es) Compuestos de carboxiamina y metodos de uso de los mismos
UY30094A1 (es) Compuestos químicos
ECSP055967A (es) N-arilheterociclos sustituidos, procedimientos para su preparación, y su empleo como medicamentos
ECSP088749A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
ECSP056201A (es) Triazolopirimidinas
ECSP056247A (es) Triazolopirimidinas
HN2010000330A (es) DERIVADOS DE INDOL-2-ONA DISUSTITUIDOS EN 3 y SU PREPARACION
UY29417A1 (es) Agentes endoparasiticidas
SE0301650D0 (sv) Novel compounds

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]